Skip to content

Surrogate markers evaluation in pre-demented Alzheimer’s disease patients and healthy elderly controls

Surrogate markers evaluation in pre-demented Alzheimer’s disease patients and healthy elderly controls

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-001756-12-BE
Enrollment
Unknown
Registered
2012-04-11
Start date
2012-04-27
Completion date
Unknown
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers and Mild Cognitive Impaired patients

Interventions

Product Name: Flutemetamol (18F) Injection Product Code: Flutemetamol (18F) Injection Pharmaceutical Form: Solution for injection CAS Number: 765922-62-1 Concentration unit: MBq/ml megabecquerel(s)/mi

Sponsors

Cliniques Universitaires Saint Luc - UCL
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Healthy elderly people, cognitively intact. - Mild Cognitive Impaired patients Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 120

Exclusion criteria

Exclusion criteria: - Significant neurological of psychiatric history and/or significant pathological lesions on MRI

Design outcomes

Primary

MeasureTime frame
Main Objective: evaluate with a multimarker approach the aMCI patients by quantitative analysis of each biomarkers by comparison to a normal database of recruited healthy volunteers. ;Secondary Objective: establish a common database of healthy volunteers with each biomarkers;Primary end point(s): - To estimate the increased discriminatory power of combination of different biomarkers in comparison to each isolated marker to identify patients at risk to convert to Alzheimer disease.;Timepoint(s) of evaluation of this end point: depending on the rate of inclusion > intermediate analysis every year until the end of the inclusion. Final analysis at the end of the clinical follow up period.

Secondary

MeasureTime frame
Secondary end point(s): Build a control group (database of normal Flutemetamol F18 scans) based on the recruitment of healthy volunteers aged from 60 to 80 years old ;Timepoint(s) of evaluation of this end point: At the end the the healthy volunteers inclusion period (control group)

Countries

Belgium

Contacts

Public ContactNuclear Medicine dpt - Dr R.Lhommel

Cliniques Universitaires Saint Luc

renaud.lhommel@uclouvain.be003227642561

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026